Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.
We performed a prospective study of discontinuation of secondary prophylaxis against cytomegalovirus (CMV) in 36 patients with acquired immunodeficiency syndrome and quiescent CMV retinitis after successful treatment with highly active antiretroviral therapy (HAART). No reactivation or progression of retinitis was observed in 35 patients with persistent response to HAART, findings that support the discontinuation of secondary prophylaxis against CMV retinitis in such patients.
Berenguer
Juan
J
Services of Infectious Diseases , Hospital Gregorio Marañón, 28007, Madrid, Spain. juaberber@eresmas.net
González
Juan
J
Pulido
Federico
F
Padilla
Belén
B
Casado
José Luis
JL
Rubio
Rafael
R
Arribas
José Rarmón
JR
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000276:immunology / Q000821:virology; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018890:Chemoprevention; D015331:Cohort Studies; D017726:Cytomegalovirus Retinitis / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies